Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 6, 1996, Pages 668-674

  Lang, Chim C ^a   Stein, C Michael ^a   He, Huai B ^a   Wood, Alastair J J ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; PLACEBO;

ADRENERGIC ACTIVITY; ADULT; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; ISOMETRIC EXERCISE; MALE; MORTALITY; NORADRENALIN RELEASE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CAPTOPRIL; DOUBLE-BLIND METHOD; EXERCISE; HEART RATE; HUMANS; MALE; NOREPINEPHRINE; RADIOISOTOPE DILUTION TECHNIQUE; RENIN; REST; SYMPATHETIC NERVOUS SYSTEM;

EID: 0030017206     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90007-7     Document Type: Article

References (35)

1. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 1977;18:27-30.
2. Khairallah PA. Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Fed Proc 1972;31:1351-7.
3. Lang CC, Rahman AR, Balfour DJK, Struthers AD. Enalapril blunts the antinatriuretic effect of circulating noradrenaline in man. J Hypertens 1993;11:565-72.
4. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984;2:581-7.
5. Guo GB, Abboud FM. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol 1984;246:H80-9.
6. Levine TB, Franciosa JA, Cohn JN. Acute and long term response to an oral converting enzyme inhibitor, captopril, in congestive heart failure. Circulation 1980;62:35-41.
7. Swedberg K, Eneroth P, Kjekhus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
8. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-23.
9. Cleland J, Semple P, Hodsman P, Ball S, Ford I, Dargie H. Angiotensin II levels, hemodynamics and sympathoadrenal function after low-dose captopril in heart failure. Am J Med 1984;77:880-6.
10. Hirsch AT, Dzau VJ. Tissue renin-angiotensin system: insights regarding the pathophysiology of heart failure. Heart Failure 1991;7:59-70.
11. Floras J, Vann Jones J, Hassan MO, Osikowska BA, Sever PS, Sleight P. Failure of plasma norepinephrine to consistently reflect sympathetic activity in humans. Hypertension 1986;8:641-9.
12. Esler MG, Jennings G, Lambert I, Meridith I, Horne M, Eisenhofer I. Overflow of catecholamine neurotransmitters to the circulation: source, fate and function. Physiol Rev 1990;70:963-85.
13. Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P. Measurement of total and organspecific norepinephrine kinetics in humans. Am J Physiol 1984;247:E21-8.
14. Stein CM, Deegan R, He HB, Wood AJJ. β-Adrenergic receptor-mediated release of norepinephrine in the human forearm. Clin Pharmacol Ther 1993;54:58-64.
15. He HB, Deegan R, Wood M, Wood AJJ. Optimization of HPLC assay for catecholamines: determination of ideal mobile phase composition and elimination of species dependent differences in extraction of 3,4-dihydroxybenzylamine. J Chromatogr 1992;574:213-8.
16. Brasch H, Sieroslawski L, Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 1993;22:699-704.
17. Majewski H, Hedler L, Schurr C, Starke K. Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II. J Cardiovasc Pharmacol 1984; 6:888-96.
18. Hayashi K, Matsumura Y, Yoshida Y, Suzuki Y, Morimoto S. The role of endogenous angiotensin II in antidiuresis and norepinephrine overflow induced by stimulation of renal nerves in anesthetized dogs. J Cardiovasc Pharmacol 1991;17:807-13.
19. Stead SW, Bloor BL. The effects of captopril on the renin-angiotensin system and the sympathetic nervous system during sodium nitroprusside-induced hypotension in the halothane-anesthetized rabbit. J Cardiovasc Pharmacol 1990;15:968-75.
20. Doward PK, Rudd CD. Influence of brain renin angiotensin system on renal sympathetic and cardiac baroreflexes in conscious rabbits. Am J Physiol 1991; 260:H770-8.
21. Oliver JA, Sciacca RR, Cannon PJ. Effect of inhibition of angiotensin II with captopril on renal overflow of norepinephrine. Hypertension 1982;4:257-63.
22. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol 1993;264:E631-7.
23. Noshiro T, Shimizu K, Way D, Miura Y, McGrath BP. Angiotensin II enhances norepinephrine spillover during sympathetic activation in conscious rabbits. Am J Physiol 1994;266:H1864-71.
24. Webb DJ, Seidelin PH, Benjamin N, Gillier JG, Struthers AD. Sympathetically mediated vasoconstriction is augmented by angiotensin II in man. J Hypertens 1988;6(suppl):S542-3.
25. Clemson B, Gaul L, Gubin SS, Campsey DM, McConville J, Nussberger J, et al. Prejunctional angiotensin II receptor: facilitation of norepinephrine release in human forearm. J Clin Invest 1994;93:684-91.
26. Taddei S, Favilla S, Duranti P, Simonini N, Salvetti A. Vascular renin-angiotensin system and neurotransmission in hypertensive persons. Hypertension 1991; 18:266-77.
27. Goldsmith SR, Haskings GJ. Subpressor angiotensin II infusions do not stimulate sympathetic activity in humans. Am J Physiol 1990;258:H179-82.
28. Goldsmith SR, Haskings GJ, Miller RN. Angiotensin II and sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol 1993;21: 1107-13.
29. Dzau VJ. Circulating versus local renin-angiotensin systems in cardiovascular homeostasis. Circulation 1988;77(suppl):14-13.
30. Owen PJ, Plevin R, Boarder MR. Characterization of bradykinin-stimulated release of noradrenaline from cultured bovine adrenal chromaffin cells. J Pharmacol Exp Ther 1989;248:1231-6.
31. Dominiak P, Blochl A. Does converting enzyme inhibition change the neuronal and extra neuronal uptake of catecholamines? Basic Res Cardiol 1991;86(suppl): 149-56.
32. Wallin BG, Morlin C, Hjemdahl P. Muscle sympathetic activity and venous plasma noradrenaline concentrations during static exercise in normotensive and hypertensive subjects. Acta Physiol Scand 1987;129: 489-97.
33. Haskings GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
34. Weber MA, Neutel JM, Smith DH. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition. Am Heart J 1992;123:1414-20.
35. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82:1724-9.